SecurityUNF / Unifirst Corp. (904708104)
IndustryPersonal Services
Common Shares Outstanding15,420,788 shares (as of 2018-02-24)
Total Insiders23
Total Directors9
Total Officers8

Stock Insider Trading (from SEC Form 4)

Unifirst Corp. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

UNF / Unifirst Corp. insiders include Katz David Martin, Evans Donald J, Ross William Masters, Iandoli Michael, Postek Thomas, Croatti Matthew, Cohen Phillip L, The Ronald D Croatti Trust - 1993, O'Connor Shane, Sintros Steven S, CAMILLI KATHLEEN M, Estate of Ronald D. Croatti, and Red Cat Management Associates, Inc., Queue Management Associates, Inc., Levenstein Cecelia, Queue Limited Partnership, CROATTI RONALD D, Red Cat Limited Partnership, DIFILLIPPO DAVID A, Croatti Michael A, Zemlin Raymond C., CROATTI CYNTHIA, Croatti Carol.

Insider Roster

Insider Dir Off 10% Shares Owned
Sintros Steven S President and CEO, Director
X X 3,023
DIFILLIPPO DAVID A Senior VP of Operations
X 5,151
Croatti Matthew 10% Owner
X
The Ronald D Croatti Trust - 1993 10% Owner
X
Estate of Ronald D. Croatti 10% Owner
X 146,400
Croatti Carol 10% Owner
X
Levenstein Cecelia 10% Owner
X
Queue Management Associates, Inc. 10% Owner
Queue Limited Partnership 10% Owner
X
CROATTI CYNTHIA Executive VP and Treasurer, Director, 10% Owner
X X X
Ross William Masters Senior VP of Operations
X 1,236
Katz David Martin Senior VP Sales and Marketing
X 1,044
Croatti Michael A Senior VP of Operations
X 54,855
Iandoli Michael Director
X 5,732
Postek Thomas Director
X
Zemlin Raymond C. Director
X
CAMILLI KATHLEEN M Director
X
Cohen Phillip L Director
X
O'Connor Shane Senior VP and CFO
X 2,102
CROATTI RONALD D President and CEO, Director, 10% Owner
X X X
Evans Donald J Director
X
Red Cat Management Associates, Inc. 10% Owner
CROATTI CYNTHIA Executive VP and Treasurer, Director, 10% Owner
Red Cat Limited Partnership 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-23 4 Sintros Steven S S D 172.65 -902 3,023 521,921
2018-05-22 4 Sintros Steven S D D 176.70 -1,764 3,925
2018-05-22 4 Sintros Steven S M D 69.05 2,666 5,689
2018-04-24 4 DIFILLIPPO DAVID A S D 161.70 -1,046 5,151 832,917
2018-04-23 4 DIFILLIPPO DAVID A D D 162.15 -1,621 6,197
2018-04-23 4 DIFILLIPPO DAVID A M D 49.67 2,667 7,818
2017-12-05 4 The Ronald D Croatti Trust - 1993 W D 31,134 31,134
2017-12-05 4 Croatti Matthew By Trust W I 31,134 31,134
2017-12-05 4 Croatti Carol By Trust W I 31,134 31,134
2018-03-28 4 DIFILLIPPO DAVID A S D 150 -993 5,151 772,650
2018-03-26 4 DIFILLIPPO DAVID A S D 150 -21 6,144 921,600
2018-03-23 4 DIFILLIPPO DAVID A D D 151.60 -1,653 6,165
2018-03-23 4 DIFILLIPPO DAVID A M D 49.67 2,667 7,818
2018-03-07 4 Ross William Masters S D 155.25 -131 1,236 191,889
2018-03-05 4 Ross William Masters D D 154.60 -203 1,367
2018-03-05 4 Ross William Masters M D 69.05 334 1,570
2018-02-26 4 DIFILLIPPO DAVID A S D 158.95 -1,266 4,851 771,066
2018-02-23 4 DIFILLIPPO DAVID A D D 157.10 -1,400 6,117
2018-02-23 4 DIFILLIPPO DAVID A M D 49.67 2,666 7,517
2018-02-20 4 Croatti Michael A S D 155.16 -1,152 54,855 8,511,302
2018-02-16 4 Croatti Michael A D D 155.05 -1,849 56,007
2018-02-16 4 Croatti Michael A M D 49.67 334 57,856
2018-02-16 4 Croatti Michael A M D 69.05 2,667 57,522
2018-02-20 4 Katz David Martin S D 155.05 -1,003 1,044 161,872
2018-02-20 4 Katz David Martin D D 155.95 -1,663 2,047
2018-02-20 4 Katz David Martin M D 69.05 2,666 3,710
2018-02-07 4 Ross William Masters S D 153 -119 1,236 189,108
2018-02-05 4 Ross William Masters D D 163.15 -214 1,355
2018-02-05 4 Ross William Masters M D 69.05 333 1,569
2018-01-18 4 Katz David Martin S D 170.85 -1,045 1,044 178,367
2018-01-18 4 Katz David Martin D D 170.50 -1,622 2,089
2018-01-18 4 Katz David Martin M D 69.05 2,667 3,711
2018-01-17 4 Croatti Michael A S D 170.26 -1,202 54,855 9,339,612
2018-01-16 4 Croatti Michael A D D 171.15 -1,798 56,057
2018-01-16 4 Croatti Michael A M D 49.67 333 57,855
2018-01-16 4 Croatti Michael A M D 69.05 2,667 57,522
2018-01-12 4 Iandoli Michael A D 234 5,732
2018-01-09 4 Postek Thomas M D 53.20 1,500 29,599
2018-01-09 4 Cohen Phillip L M D 53.20 1,500 13,051
2018-01-08 4 Ross William Masters S D 171.70 -125 1,236 212,221
2018-01-05 4 Ross William Masters D D 175.05 -208 1,361
2018-01-05 4 Ross William Masters M D 69.05 333 1,569
2017-12-20 4 CROATTI CYNTHIA A D 1,332 2,873,303
2017-12-20 4 Croatti Michael A A D 1,044 54,855
2017-12-20 4 Katz David Martin A D 1,044 1,044
2017-12-20 4 Ross William Masters A D 1,044 1,236
2017-12-20 4 DIFILLIPPO DAVID A A D 1,044 4,851
2017-12-18 4 Katz David Martin S D 168.15 -1,060 0
2017-12-18 4 Katz David Martin D D 167.95 -1,607 1,060
2017-12-18 4 Katz David Martin M D 69.05 2,667 2,667
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Unifirst (UNF) Soars to a 52-Week High, Time to Cash Out?

2018-05-22 zacks
Have you been paying attention to shares of Unifirst (UNF - Free Report) ? Shares have been on the move with the stock up 9.8% over the past month. UNF hit a new 52-week high of $178.03 in the previous session. Unifirst has gained 7.2% since the start of the year compared to the -4.9% move for the Industrial Products sector and the 15.2% year-to-date return for its peer group. (31-0)

Top Dividend Raises For April 2018

2018-05-07 seekingalpha
Dividend growth investing is a popular model followed by the investing community to build assets. Companies which not only pay dividends, but raise them year after year have been shown to perform better overall for investor returns. (102-0)

Zacks.com featured highlights include: NetApp, Steel Dynamics, UniFirst, Reliance Steel and Stepan

2018-04-25 zacks
Chicago, IL – April 25, 2018 - Stocks in this week’s article NetApp, Inc. (NTAP - Free Report) , Steel Dynamics, Inc. (STLD - Free Report) , UniFirst Corporation (UNF - Free Report) , Reliance Steel & Aluminum Co. (RS - Free Report) and Stepan Company (SCL - Free Report) . (17-0)

5 Stellar Relative Price Strength Stocks for Assured Returns

2018-04-24 zacks
Investors generally gauge a stock’s potential return by examining earnings growth and valuation multiples. At the same time, it’s important to measure the performance of such a stock relative to its industry or peers, or the appropriate benchmark. (58-0)

Bull of the Day: Korn Ferry (KFY)

2018-04-20 zacks
Korn/Ferry International (KFY - Free Report) is cashing in on the strong global staffing trends. This Zacks Rank #1 (Strong Buy) is expected to grow earnings by the double digits both in Fiscal 2018 and Fiscal 2019. Korn Ferry is an organizational consulting firm which specializes in executive search. Headquartered in Los Angeles, it has 7,000 employers in more than 50 countries. A Big Beat in the Third Quarter of Fiscal 2018 On Mar 6, Korn Ferry reported its fiscal third quarter 2018 results and blew past the Zacks Consensus Estimate by $0. (8-0)